Patented Digital Therapeutics IP
Personalized dosing intelligence for complex, multi‑drug regimens — ready to license.
Licensable IP and technology for multi‑drug dose optimization and symptom‑trigger analytics — built from real‑world prototypes and validated in a COVID‑era beta for symptom tracking.
The Problem: Multi-drug dosing is broken
22% of U.S. adults take 5+ medications simultaneously. Current tools offer binary interaction flags—not individualized dose optimization. The result: preventable adverse events, suboptimal efficacy, and escalating healthcare costs.
Market Size
22.4% of U.S. adults (40–79) take ≥5 medications. In older adults (65+), this rises to ~40%. The polypharmacy market represents a significant and growing opportunity.
Unmet Need
Existing solutions are reactive checklists, not predictive optimization engines. Clinicians lack tools that model regimen-level interactions and cumulative effects across multiple medications.
Regulatory Tailwinds
FDA guidance increasingly emphasizes real-world evidence and personalized dosing. Digital therapeutics and remote monitoring are gaining regulatory acceptance and reimbursement.
Our Solution: Patented IP with clear competitive moat
OptimDosing's technology is protected by granted U.S. patents and international applications, creating a defensible position in the multi-drug optimization space.
Multi‑drug Optimization Engine
Patented logic engine and algorithms to individualize dosing using patient + population data — beyond simple interaction flags. Accounts for cumulative toxicity, therapeutic overlap, and patient-specific factors.
Symptom‑Trigger Analytics
Track nutrition, medication, lifestyle, and device data to isolate probable triggers and progression patterns. Validated in real-world beta deployments for symptom tracking and correlation analysis.
Enterprise‑ready Integration
Positioned for licensing to pharma, digital health, and chronic‑care platforms. SDK/API or white‑label integration. API-first architecture designed for rapid deployment and scalability.
Who we partner with
Pharma & biotech • Digital therapeutics • Medtech • Chronic‑care platforms
Pharma & Biotech
Use our IP to design smarter dosing regimens and combination therapy studies. Accelerate development timelines, improve safety profiles, and strengthen regulatory submissions with evidence-based dosing rationale.
Digital Health Platforms
Embed dosing logic and symptom‑trigger modules into your product stack. Differentiate your offering with patented technology that goes beyond basic medication reminders to provide clinical decision support.
Providers & Payers
Decision support for polypharmacy in aging populations and complex care. Reduce adverse events, improve outcomes, and lower costs through optimized medication management.
Why OptimDosing: Competitive advantages
🔒 Patent Protection
Granted U.S. patents (US12009109B2, US12347538B2) and international applications create a defensible moat. Core algorithms and methods are protected, not just the implementation.
🧪 Validated Technology
Real-world prototype deployed during COVID-19 for symptom tracking. Technology has been tested in production environments, not just theoretical models.
📊 Evidence-Based Approach
Combines clinical trial data, real-world evidence, and patient-specific factors. Goes beyond rule-based systems to provide individualized, data-driven recommendations.
Business Model: Licensing & Acquisition
OptimDosing is positioned for licensing to established players or acquisition by strategic buyers. The IP portfolio, validated technology, and clear market need create multiple exit pathways. We're actively engaging with pharma, digital health companies, and strategic acquirers.